
    
      Standard of care treatment will be with either prednisolone 40 mg/day for 28 days or
      pentoxifylline 400 mg TID for 28 days. The patient's physician will decide the standard of
      care treatment the patient will receive. Patients will be randomized (1:1) to receive either
      no additional drug treatment (SOC group) or to receive a pegfilgrastim (NeulastaÂ®, 6 mg) SQ.

      Patients will be seen in-person at screening, randomization (Day 1), Day 8, Day 29, Week 12,
      and Week 24. Safety examination and blood tests will be performed. In addition, biological
      specimens will be saved for research purposes at these time points.

      Total duration of patient participation is 24 weeks.
    
  